Interleukin-6: obstacles to targeting a complex cytokine in critical illness

OJ McElvaney, GF Curley, S Rose-John… - The Lancet …, 2021 - thelancet.com
Circulating concentrations of the pleiotropic cytokine interleukin-6 (IL-6) are known to be
increased in pro-inflammatory critical care syndromes, such as sepsis and acute respiratory …

Characterization of the inflammatory response to severe COVID-19 illness

OJ McElvaney, NL McEvoy, OF McElvaney… - American journal of …, 2020 - atsjournals.org
Rationale: Coronavirus disease (COVID-19) is a global threat to health. Its inflammatory
characteristics are incompletely understood. Objectives: To define the cytokine profile of …

A review of alpha-1 antitrypsin binding partners for immune regulation and potential therapeutic application

ME O'Brien, G Murray, D Gogoi, A Yusuf… - International Journal of …, 2022 - mdpi.com
Alpha-1 antitrypsin (AAT) is the canonical serine protease inhibitor of neutrophil-derived
proteases and can modulate innate immune mechanisms through its anti-inflammatory …

Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications

OF McElvaney, T Asakura, SL Meinig… - …, 2022 - thelancet.com
Summary Background Interleukin-6 (IL-6) is elevated in SARS-CoV-2 infection. IL-6
regulates acute-phase proteins, such as alpha-1 antitrypsin (AAT), a key lung anti-protease …

Post-translational modifications of circulating alpha-1-antitrypsin protein

U Lechowicz, S Rudzinski, A Jezela-Stanek… - International Journal of …, 2020 - mdpi.com
Alpha-1-antitrypsin (AAT), an acute-phase protein encoded by the SERPINA1 gene, is a
member of the serine protease inhibitor (SERPIN) superfamily. Its primary function is to …

Plasma markers of COVID-19 severity: a pilot study

J Beimdiek, S Janciauskiene, S Wrenger, S Volland… - Respiratory …, 2022 - Springer
Background SARS-CoV-2 infected patients show heterogeneous clinical presentations
ranging from mild symptoms to severe respiratory failure and death. Consequently, various …

Severe COVID-19 illness and α1-antitrypsin deficiency: COVID-AATD study

JL Rodríguez Hermosa, G Vargas Centanaro… - Biomedicines, 2023 - mdpi.com
Background: Epidemiologic studies have reported that the geographical distribution of the
prevalence of allelic variants of serine protein inhibitor-A1 (SERPINA1) and severe cases of …

Alpha-1 antitrypsin deficiency: current therapy and emerging targets

OF McElvaney, DD Fraughen… - Expert Review of …, 2023 - Taylor & Francis
Introduction Alpha1 antitrypsin deficiency (AATD), a common hereditary disorder affecting
mainly lungs, liver and skin has been the focus of some of the most exciting therapeutic …

Diagnosis and management of cystic fibrosis exacerbations

T Milinic, OJ McElvaney… - Seminars in respiratory and …, 2023 - thieme-connect.com
With the improving survival of cystic fibrosis (CF) patients and the advent of highly effective
cystic fibrosis transmembrane conductance regulator (CFTR) therapy, the clinical spectrum …

Alpha-1-antitrypsin antagonizes COVID-19: a review of the epidemiology, molecular mechanisms, and clinical evidence

X Bai, T Schountz, AM Buckle, JL Talbert… - Biochemical Society …, 2023 - portlandpress.com
Alpha-1-antitrypsin (AAT), a serine protease inhibitor (serpin), is increasingly recognized to
inhibit SARS-CoV-2 infection and counter many of the pathogenic mechanisms of COVID …